[1] The purpose of this review paper is to analyze the role of the kidney in glucose homeostasis, emphasizing in SGLT2 inhibition as a new therapeutic target for diabetes management. placebo ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

Researchers identified 1924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 events among the 5877 patients who used a GLP-1 RA.

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

The SGLT2 medications canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are approved by the FDA for the treatment of Type 2 diabetes. To analyze the impact of these two classes of ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 diabetes (T1D), according to a research letter published online October 23 in the Journal of the American ...

and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 diabetes (T1D), according to a research letter published online in the Journal of the American Medical Association.

SGLT2 inhibition is an innovative strategy for the management of type 2 diabetes. Apart from the main glucosuric effect, the improved glycemic control and the significant HbA1c reduction ...